Portuguese recommendations for the treatment of atopic dermatitis with biologic therapy and JAK inhibitors in adult patients

Abstract

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution) Time frame: Since the initial planning of the work 1 All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.

Dupilumab in patients with atopic dermatitis: assessing treatment response, clinical features and potential biomarkers in real-life

“…Discrepancy between the patients´ subjective assessment and the physicians objective evaluation of AD control has been discussed previously (14). We thus agree with the relevance of patient perception and self-reported assessment tools when assessing response to dupilumab treatment, namely DLQI, NRSpruritus and NRS-sleep, since it is recognized that chronic pruritus and sleep deprivation secondary to AD have a significant negative impact on the quality of life and affect different aspects such as mood, sexual activity, social interaction, work and academic activity (15,16). In our study, 9 patients were classified as responders, solely on the basis of subjective and self-reported NRS-pruritus and/or DLQI quality of life scale, while not meeting defined criteria for clinical response in the EASI and/or SCORAD disease severity scores.…”

A systematic review and meta‐analysis of investigating the mutual impact of COVID‐19 and psoriasis: Focusing on COVID‐19 course in psoriasis and the opinion on biologics in this setting

“…For various reasons, some patients have discontinued their medicine, either with or without consulting a dermatologist. At the onset of the pandemic, there was disagreement among dermatologists on the continuation or initiation of biologic drugs due to a lack of reliable evidence on the course of COVID‐19 in psoriatic patients and the effect of biologics on the disease 39,40 . Additionally, patients' attitudes toward receiving treatment changed in this period because of difficulties accessing healthcare (quarantine and isolations) or concerns about the safety of these drugs 41,42 …”

“…At the onset of the pandemic, there was disagreement among dermatologists on the continuation or initiation of biologic drugs due to a lack of reliable evidence on the course of COVID-19 in psoriatic patients and the effect of biologics on the disease. 39,40 Additionally, patients' attitudes toward receiving treatment changed in this period because of difficulties accessing healthcare (quarantine and isolations) or concerns about the safety of these drugs. 41,42 A study by Kartal et al included a large population of 1827 psoriasis patients receiving conventional immunosuppressive (methotrexate and cyclosporine) and systemic biologic therapy (anti-TNF or anti-IL drugs).…”

Practical guide for the use of immunobiologic agents in allergic diseases - ASBAI

“…The Portuguese guideline for the systemic therapy of atopic dermatitis recommends evaluation after 3 and 6 months of treatment, using the EASI-50 and EASI-75, NRS of pruritus and DLQI, as described in Table 8. 52…”